Ginkgo Bioworks Q1 revenue up 27% to $48M, guided revenue raised; net loss narrows to $91M

Ginkgo Bioworks Holdings, Inc.

2025-Q1 EPS reported -$1.68 revenue$48,318,000

Q1 2025 total revenue $48M (+27% YoY); core revenue ex-deferred release $41M (+8%). GAAP net loss $(91)M vs $(166)M prior year.
Adjusted EBITDA $(47)M improved from $(117)M; cash & equivalents $517M.
Raises FY2025 total revenue guidance to $167-187M (from $160-180M); Cell Eng. guidance $117-137M.
Cost reduction target: $250M annualized by Q3 2025; achieved $205M run-rate in Q1.
Awarded $29M ARPA-H contract for distributed manufacturing using wheat germ cell-free systems.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.